drugset / Trial / NCT03115762
Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial will investigate the pharmacokinetic,immunogenicity and safety biosimilarity of ASKB1202 compared to bevacizumab sold in China and Europe.
Timeline
- Start
- 2017-06
- Primary completion
- 2017-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKB1202 | Unknown | — | Intravenous |
| Comparator | Bevacizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.